Rating #38
Hari Hariharan
Nwi Management
Portfolio value
Stocks
Performance
1 Year
+22.20%
Stock Holdings
$
%
1Y
3Y
5Y
10Y
Hari Hariharan’s Portfolio: Q3 2025
Top10 stocks: 57.17% of the portfolio
Hari Hariharan’s Trades: Q3 2025
Adds
New Buys
Sold Outs
Cuts
4.08ppt
1.41ppt
1.99ppt
1.31ppt
0.37ppt
Company Name | Share Count Chg. (%) | Price Paid | Buy Value | Portfolio % Change | |
|---|---|---|---|---|---|
1  INSM | +41.81% | $122.51 | $36.88M | 4.08ppt | |
+100.00% | $2400.46 | $29.77M | 1.41ppt | ||
3  NU | +100.05% | $13.95 | $27.91M | 1.99ppt | |
+11.98% | $13.95 | $8.95M | 1.31ppt | ||
5  AMZN | +100.00% | $226.35 | $7.13M | 0.37ppt |
Hari Hariharan’s Holdings: Q3 2025
Company Name | Primary Industry | Avg. price paid  | Share Count Chg. (%) | No of shares held | Market value | Portfolio % Change | % of Ownership | Holding period | Last Transaction | |
|---|---|---|---|---|---|---|---|---|---|---|
- | $241.96 | +100.00% | 1.00M | $241.96M | 12.90% 12.90ppt | - | 1 Quarter | Q3 2025 | ||
2 INSM | Pharmaceutical Pres | $101.09 | +41.81% | 1.02M | $147.03M | 7.84% 4.08ppt | 0.54% | 5 Quarters | Q3 2025 | |
3  NTRA | Medical Laboratories | $135.45 | -2.25% | 830.30K | $133.65M | 7.13% -0.31ppt | 0.61% | 6 Quarters | Q3 2025 | |
4  MELI | Other Business Services | $1700.44 | 0.00% | 42.70K | $99.79M | 5.32% -0.47ppt | 0.08% | 4 Quarters | Q1 2025 | |
Finance Services | $13.96 | +11.98% | 6.00M | $96.06M | 5.12% 1.31ppt | - | 2 Quarters | Q3 2025 | ||
- | $32.98 | +100.00% | 2.50M | $82.45M | 4.40% 4.40ppt | - | 1 Quarter | Q3 2025 | ||
- | $139.17 | +100.00% | 540.00K | $75.15M | 4.01% 4.01ppt | - | 1 Quarter | Q3 2025 | ||
Retail-Catalog & Mail-Order | $219.57 | +100.00% | 300.00K | $65.87M | 3.51% 3.51ppt | - | 1 Quarter | Q3 2025 | ||
Commodity Brokers & Dealers | $65.00 | +100.00% | 1.00M | $65.00M | 3.47% 3.47ppt | - | 1 Quarter | Q3 2025 | ||
10 I IBIT | Commodity Brokers & Dealers | $65.00 | +100.00% | 1.00M | $65.00M | 3.47% 3.47ppt | 0.07% | 1 Quarter | Q3 2025 | |
11 NU | Finance Services | $14.87 | +100.05% | 4.00M | $64.05M | 3.41% 1.99ppt | 0.08% | 2 Quarters | Q3 2025 | |
12 MELI Call | Other Business Services | $2143.91 | +100.00% | 24.80K | $57.96M | 3.09% 1.41ppt | - | 5 Quarters | Q3 2025 | |
13 NTRA Call | Medical Laboratories | $160.97 | +100.00% | 267.70K | $43.09M | 2.30% 2.30ppt | - | 1 Quarter | Q3 2025 | |
14  TEVA | Pharmaceutical Pres | $17.97 | 0.00% | 2.07M | $41.71M | 2.22% 0.43ppt | 0.18% | 4 Quarters | Q2 2025 | |
15 I SLV Call | Commodity Brokers & Dealers | $32.81 | -70.16% | 979.70K | $41.51M | 2.21% -3.37ppt | - | 2 Quarters | Q3 2025 | |
16 I IFS | Other Commercial Banks | $41.30 | 0.00% | 1.02M | $40.89M | 2.18% 0.18ppt | 0.91% | 24 Quarters | Q4 2019 | |
17  ARM Call | Semiconductors | $141.49 | +100.00% | 250.00K | $35.37M | 1.89% 1.89ppt | - | 1 Quarter | Q3 2025 | |
18 ARM | Semiconductors | $128.77 | 0.00% | 225.00K | $31.84M | 1.70% -0.19ppt | 0.02% | 3 Quarters | Q2 2025 | |
19  MSFT | Prepackaged Software | $377.48 | 0.00% | 57.10K | $29.58M | 1.58% 0.10ppt | 0.00% | 25 Quarters | Q2 2025 | |
- | $52.06 | +100.00% | 566.90K | $29.51M | 1.57% 1.57ppt | - | 1 Quarter | Q3 2025 |
NEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersNEWSLETTER
Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2026, S&P Global Market Intelligence. All rights reserved.
View Data ProvidersGainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.